glp-1 receptor agonist brands list 5 trends to expect in 2026: Expanded uses, oral options, and more 2025’s Breakthrough GLP-1 Obesity Treatments:
Description
Given the large and increasing number of currently developed novel agents within the class of GLP-1RAs (127, 128), it can be anticipated that there will be increasing competition to achieve better tolerability and safety

Free fatty acid receptors FFAR1 and GPR120 as novel therapeutic targets for metabolic disorders

Penn Researchers Use AI to Surface Unreported GLP-1 Side Effects in Reddit Posts
Today, GLPs can be generally classified into 2 categories long acting (administered once weekly) or short acting (administered daily), though most remain approved only for treatment of DM

Inclusion and exclusion criteria Studies were eligible if they: (1) reported on the use of GLP-1 RAs in women planning pregnancy, during preconception, or in early pregnancy
